trastuzumab,fulvestrant,tucatinib
seagen
['sgntuc-019', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib']
 sgntuc-019: tucatinib &amp; trastuzumab for her2+ biliary tract cancer #asco23 phs-ii, 30 pts, her2 overexpression/amplification orr: 46.7%, dor 6.0mo, dcr 76.7% mpfs 5.5 mo, 12-mo os rate 53.8% supports tuc/tras as ctx-free option 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology